moxifloxacin has been researched along with pbtz169 in 2 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (pbtz169) | Trials (pbtz169) | Recent Studies (post-2010) (pbtz169) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 50 | 0 | 47 |
| Protein | Taxonomy | moxifloxacin (IC50) | pbtz169 (IC50) |
|---|---|---|---|
| Cytochrome P450 2C19 | Homo sapiens (human) | 3.77 | |
| Decaprenylphosphoryl-beta-D-ribose oxidase | Mycobacterium tuberculosis H37Rv | 0.01 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kumari, D; Perveen, S; Sharma, R; Singh, K | 1 |
| Chen, X; Fu, L; Lu, Y; Qi, X; Wang, B; Wang, H; Zhang, W; Zheng, L | 1 |
1 review(s) available for moxifloxacin and pbtz169
| Article | Year |
|---|---|
Tuberculosis drug discovery: Progression and future interventions in the wake of emerging resistance.
Topics: Antitubercular Agents; Diarylquinolines; Drug Therapy, Combination; Ethambutol; Extensively Drug-Resistant Tuberculosis; Humans; Isoniazid; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Pyrazinamide; Rifampin | 2022 |
1 other study(ies) available for moxifloxacin and pbtz169
| Article | Year |
|---|---|
Efficacy of PBTZ169 and pretomanid against Mycobacterium avium,
Topics: Animals; Anti-Bacterial Agents; Clofazimine; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium abscessus; Mycobacterium avium; Mycobacterium chelonae; Mycobacterium fortuitum; Mycobacterium Infections; Mycobacterium Infections, Nontuberculous; Nontuberculous Mycobacteria; Rifabutin | 2023 |